Cipla signs binding term sheet to sell its entire stake in Saba Investments; Deal worth US$6.50 million

Indian multinational pharmaceutical company Cipla Limited announced the sale of its entire stake in Saba Investments Limited on 15 May 2023. Saba Investments Limited is a UAE-based Joint Venture between Cipla Limited and Shibam Group Holding Limited.

Indian rupee notes
(Image: MeelBijendra/Gitika)

Read Also: Tech Mahindra Ltd approves proposal to increase stake in Tech Mahindra Arabia Ltd to 80% by acquiring additional 29% shares; Acquisition cost $11.1 million

Cipla Limited signed a binding term sheet to sell its entire 51% stake in Saba Investment Limited to Shibam Group Holding Limited for a settlement value of US$ 6.50 million.

Cipla Limited holds 51% stake and Shibam Group Holding Limited holds 49% stake in Saba Investment Limited.

Cipla mainly manufactures drugs for the treatment of heart diseases, diabetes, arthritis, respiratory etc. and it is the third largest pharmaceutical company in India.

Shibam Group Holding Limited primarily engaged in investment activities in commercial, industrial, and real estate undertakings and is a company incorporated under the laws of Ras Al Khaimah International Corporate Centre, UAE.

Read Also: Go First Collapse Explained: what and why Go First Airline faced bankruptcy crisis

According to the binding term sheet between Cipla and Shibam Group Holding “the proposed sale is subject to the signing of a definitive agreement” – Within 120 days from the date of signing of the binding term sheet i.e. May 15, 2023 or on satisfaction of the closing conditions as agreed in the definitive agreement, whichever is earlier; or such other date as may be mutually agreed between the parties – on which the deal is expected to be completed.

Consequent to the sale of the entire stake, Saba Investment Limited and its subsidiaries namely Cipla Middle East Pharmaceuticals FZ LLC, UAE (CME) and Cipla Medica Pharmaceutical & Chemical Industries Limited, Yemen (Cipla Medica), will cease to be subsidiaries of Cipla Limited, the company said.

Read Also: Adani Ports Approves Tender Offer to Purchase Up to $130 Million in Cash in the Aggregate Principal Amount of the Outstanding 3.375% Senior Notes

Cipla Medica Pharmaceutical & Chemical Industries Limited (Cipla Medica) reported revenue of USD 9.65 million for the fiscal year ending March 31, 2023, while Cipla Middle East Pharmaceuticals FZ LLC (CME) reported revenue of USD 14.82 million in the same period.

Shares of Cipla Ltd rose by 1.05% to Rs.932.45 on the NSE.

Read Also: Deepak Nitrite Q4 FY23: Net profit declined by 12.48% YoY to Rs 233.86 crore; Declared dividend of Rs 7.50 per share